Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adult Patients
25%
Allergic Reaction
25%
Anti-spike
15%
Antibody Deficiency
35%
Antibody Response
28%
Antireceptor
10%
B Cell Response
10%
Basophils
12%
Booster Dose
25%
Complement Activation
18%
COVID-19
35%
Cytokine Response
6%
Gene Encoding
6%
Gene Sequencing
25%
Glycol
12%
Healthy Donors
9%
Healthy Individuals
7%
IgG1
25%
Immune Deficiency
8%
Immunodeficiency
25%
Immunoglobulin
16%
Immunoglobulin Prophylaxis
8%
Immunoglobulin Replacement
40%
Immunophenotyping
6%
Interleukin-13 (IL-13)
6%
Interleukin-1β
6%
Memory B Cells
7%
Memory B-cell Response
25%
Monocytes
6%
MRNA Vaccine
37%
Neutralizing Activity
35%
Neutralizing Antibodies
10%
Non-allergic
12%
Novel Nanoparticles
6%
Number of Individuals
6%
Omicron Variant
29%
Primary Antibody Deficiency
50%
Primary Vaccination
10%
Protective Behavior
9%
Reaction Mechanism
25%
Receptor Binding Domain
10%
Replacement Product
40%
SARS-CoV-2 Infection
25%
SARS-CoV-2 mRNA Vaccination
25%
SARS-CoV-2 Vaccine
7%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
62%
T Cell Response
7%
Titer
10%
Vaccination
13%
Vaccine Boosting
25%
Immunology and Microbiology
Allergy
25%
Antibody Response
28%
Antibody Titer
6%
B Cell
10%
Basophil
16%
Basophil Activation
16%
C3a (Complement)
8%
Chromatin
8%
Complement Activation
25%
Complement Component 5a
8%
Complement Component C5a Receptor
8%
COVID-19
35%
Cytokine Response
8%
Gene Sequence
25%
Humoral Immune Deficiency
50%
Hypersensitive Response
25%
Immune Response
7%
Immunodeficiency
25%
Immunodeficiency
5%
Immunoglobulin E
8%
Immunoglobulin G1
25%
Immunoglobulin M
8%
Infection
32%
Infectious Disease
32%
Interleukin 13
8%
Intravenous Immunoglobulin
41%
Lung
5%
Memory B Cell
25%
Monocyte
8%
Mononuclear Phagocyte
8%
Omicron Coronavirus Variant
31%
Receptor Binding
12%
Receptor Blocking
8%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Spike
15%
T Cell
7%
Titer
8%
Toll-Like Receptor
8%
Vaccine Hesitancy
8%
